A. Voissière

Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept

J. Chezal, E. Miot-Noirault, F. Raes, 2017, Oncotarget.

Relevance of the combination of external beam radiotherapy with the hypoxia-activated prodrug ICF05016 in an experimental model of extraskeletal myxoid chondrosarcoma

J. Chezal, E. Miot-Noirault, F. Degoul, 2020, Investigational New Drugs.

Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.

J. Chezal, E. Miot-Noirault, Aurélien Voissière, 2018, European journal of medicinal chemistry.

Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.

J. Chezal, E. Miot-Noirault, S. Tarrit, 2020, Bioorganic chemistry.

CD4 T cells and neutrophils contribute to epithelial-mesenchymal transition in breast cancer

C. Caux, A. Puisieux, P. Saintigny, 2023, bioRxiv.

The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer - results from a phase 1 study

I. Treilleux, C. Caux, Christine, 2023, medRxiv.

Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs.

E. Miot-Noirault, E. Jouberton, Aurélien Voissière, 2022, American journal of cancer research.

Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept

J. Chezal, E. Miot-Noirault, M. Dauplat, 2016, Molecular Cancer Therapeutics.

Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing

J. Chezal, E. Miot-Noirault, E. Jouberton, 2017, PloS one.